Lead Product(s) : Ziritaxestat
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Primary Endpoint Achieved with Ziritaxestat in Novesa Trial in Systemic Sclerosis Patients
Details : Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.
Product Name : GLPG1690
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2020
Lead Product(s) : Ziritaxestat
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable